Curriculum Registration

Advanced Endometrial Cancer in the Immunotherapy Age

Time Commitment: 4 hours over 56 days
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Family Medicine, Internal Medicine, Hematology, Hematology/Oncology, Oncology, Women's Health, Gynecologic Oncology, Gynecologic Oncology
Credits Available: 4.0 AMA PRA Category 1 Credit™

Endometrial cancer is among the few cancers increasing in incidence and mortality in the United State and remains the most common gynecologic cancer diagnosed. To improve clinical outcomes, clinicians treating patients with endometrial cancer need to understand the molecular classification of the disease, the newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events as well as be cognizant of how best to address racial disparities in care. This educational initiative will allow clinicians to learn and discuss these crucial points in diagnosing and managing these patients to increase long-term survival. Given the rapid shift in best practices occurring in this area and the fact that current NCCN Guidelines classify endometrial cancers into 1 of 4 molecular groups, as opposed to the traditional 2 groups, it is important for clinicians to stay up to date as advances in areas such as biomarker research continue to be made. This educational activity allows clinicians to engage in interprofessional discussions with knowledgeable experts and peers to more fully understand how to integrate these new treatment approaches into their day-to-day practice and establish actionable plans to improve outcomes for their patients.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:
Forgot Password

Register

Step 1 of 3

Lilie Lin

Lilie Lin
Professor

Dr. Lilie Lin is a Professor in the Department of Radiation Oncology at the University of Texas, MD Anderson Cancer Center. She has been extensively involved in developing and implementing clinical and translational research protocols for patients with gynecologic and breast cancers. She is the principal investigator of multiple investigator initiated therapeutic studies combining novel agents with radiotherapy. Additionally, her research program is focused on identifying imaging (Magnetic Resonance Imaging(MRI)/Positron Emission Tomography (PET)) and tissue biomarkers of toxicity and poor response to therapy. She is passionate about improving outcomes for women with cervical cancer globally. She maintains an active collaboration with colleagues at the Cancer Diseases Hospital to build capacity in clinical research and research. Her research has been funded by the National Cancer Institute, Department of Defense, and multiple philanthropic foundations.